Swiss Peptide CDMO Manufacturers (2026)

Switzerland hosts the three companies that define the global peptide CDMO market: Bachem, PolyPeptide Group, and the peptide-relevant capacity inside Lonza. Together they sit on top of a global peptide therapeutics CDMO market projected to grow from USD 2.9 billion in 2025 to USD 9.0 billion by 2036, a 10.8% CAGR driven primarily by GLP-1 receptor agonists and a deeper pipeline of metabolic, oncology, and antimicrobial peptides.

Why Swiss Peptide CDMOs Now

Switzerland’s chemical and pharmaceutical industry exported CHF 152.1 billion in 2025, growing 2.2% year over year and accounting for 53% of all Swiss exports. Pharmaceutical products alone reached CHF 118.4 billion, or 41.3% of Swiss exports excluding gold, according to scienceindustries. The EU absorbed CHF 80.3 billion, while the United States grew 9.0% to CHF 36.7 billion.

Peptides are no longer a quiet corner of this export base. The success of semaglutide and tirzepatide pulled the entire peptide manufacturing ecosystem out of small-molecule’s shadow. Solid-phase peptide synthesis (SPPS), once a niche capability, is now a strategic bottleneck for some of the largest pharma companies on earth, and Swiss CDMOs sit on most of the proven commercial-scale capacity.

That sounds like a market position that sells itself. It does not. Anchor contracts with the largest GLP-1 sponsors are public knowledge, but commercial peptide demand also fragments into hundreds of smaller programs: ADC linkers, antimicrobial peptides, peptide-drug conjugates, diagnostic peptides, and an increasingly active biotech pipeline. Reaching the development directors, CMC leads, and procurement teams running those programs requires more than trade fair presence and a tier-one reputation.

The Three Anchors: Bachem, PolyPeptide, Lonza

Bachem: scaling toward a metric ton per site

Bachem holds roughly 16.8% of the global peptide therapeutics CDMO market and is the only Swiss-headquartered pure-play peptide CDMO. In November 2025, the company secured a CHF 1 billion peptide supply contract covering deliveries from 2025 through 2029. CEO Thomas Meier said long-term collaborations “enable us to reliably plan” capacity expansion and “help us meet our growth targets.”

Bachem is investing aggressively across four sites. The company is expanding Bubendorf (Building K), upgrading Vista, California toward a target of nearly one metric ton of annual peptide output, refining diagnostic peptide capacity in St Helens, UK, and beginning concept design in 2025 for a completely new large-scale site at Sisslerfeld in Aargau. As Bachem itself puts it, “pharmaceutical companies and suppliers together do not have enough capacity to produce the required APIs today.”

PolyPeptide: GLP-1 demand reshaping the income statement

PolyPeptide Group closed financial year 2025 with revenue of approximately EUR 389 million, up 15.6% year over year, with EBITDA margin improving from 7.5% in 2024 to a guided 11 to 12% range. Capital expenditure was just over EUR 100 million. CEO Juan José Gonzalez attributed the result to “improved execution across our multi-site network, a rich development pipeline, and rapid growth” in metabolic therapeutics, with significant exposure to GLP-1 programs.

PolyPeptide is headquartered in Baar, with peptide manufacturing across Switzerland, Belgium, Sweden, France, India, and the United States. The multi-site footprint gives the company unusual flexibility on capacity allocation, but it also multiplies the number of customer touchpoints that need orchestrated commercial coverage.

Lonza: drug substance plus large-scale fill-finish

Lonza is not a pure-play peptide CDMO, but its synthesis platforms in Visp and its newly operational drug-product capacity in Stein are highly relevant to peptide-finished-dose programs. Lonza’s $521 million Stein fill-finish facility, announced in 2022, received Swissmedic GMP approval in October 2025 and is now operational for vial and lyophilized drug-product manufacturing. The campus complements Lonza’s drug substance footprint and gives existing peptide customers an end-to-end Swiss route from API to filled vial.

Together, these three players account for the majority of commercial-scale peptide capacity in continental Europe. The supporting cluster around Visp, Bubendorf, Sisslerfeld, and the Basel area also includes specialty players in custom peptide synthesis, ADC linker chemistry, and conjugation services, most of which export 70 to 90% of their output.

The GLP-1 Effect Goes Beyond Novo and Lilly

The conventional narrative says peptide CDMOs are sold out on GLP-1 work for the next several years. Partly true. Tier-one biologics and peptide CDMOs have seen lead times extend 30 to 50% since 2023, and minimum-volume commitments have hardened.

But the same dynamic has created a second wave of demand that the anchor accounts cannot fill:

• Biosimilar GLP-1 developers preparing for semaglutide patent expirations beginning around 2026
• Next-generation metabolic peptides including dual and triple agonists
• Oncology peptides and PDCs (peptide-drug conjugates) with growing clinical-stage activity
• Antimicrobial peptides as the WHO antibiotic resistance pipeline matures
• Diagnostic peptides for imaging and theranostics
• ADC linker peptides for the rapidly expanding antibody-drug conjugate market

Each of these segments contains tens to hundreds of small and mid-cap biotechs buying peptide capacity for the first time, often through a procurement function that is itself new. They are exactly the audience traditional Swiss CDMO commercial models are worst at reaching.

Why Conventional Channels Are Saturated for Peptides

Swiss peptide CDMOs have leaned on a familiar mix of channels for two decades. Each one is showing diminishing returns in the post-GLP-1 environment.

Trade fairs: CPHI Worldwide, DCAT Week, BIO-Europe, Swiss Biotech Day

CPHI Frankfurt 2025 attracted more than 62,000 professionals and 2,400 exhibiting firms across three days at Messe Frankfurt. DCAT Week 2026 brings over 10,000 professionals from 700+ companies to New York for the industry’s most concentrated dealmaking window. Both events are essential for relationship maintenance with anchor accounts. Neither is an efficient prospecting tool for new business.

A peptide CDMO booth at CPHI Frankfurt typically costs $30,000 to $80,000+ before staffing, materials, and travel. You meet whoever walks past, mostly procurement contacts at established pharma. The Phase II biotech CMC director who needs 5 kg of clinical peptide next year is not walking past your booth. They are at the SOT meeting, or BIO International, or a small antimicrobial-peptide symposium with 200 attendees. Cost per qualified lead from major pharma fairs: $300 to $900+.

Scientific KOL networks and academic collaborations

The peptide world is small. Many commercial relationships still trace back to academic SPPS pedigree, advisory boards, and senior chemists who know each other from Bachem reunions or Merrifield-lineage labs. This channel works but does not scale. A KOL relationship takes months to develop, covers a narrow therapeutic area, and depends on personal chemistry. You cannot KOL-network into 200 target accounts simultaneously when each chemistry director sits inside a different therapeutic silo.

Distributor and trading-house arrangements

Less common in peptides than in small-molecule APIs, but still present for catalog and custom-research peptides. Distributors take 8 to 20% margin and own the buyer relationship. When a customer scales from research-grade to GMP, the distributor often loses the program, but the manufacturer rarely learns who the customer was in the first place.

Field sales representatives

Effective for named accounts, brutally expensive everywhere else. A peptide-experienced commercial lead covering one European territory costs $150,000 to $250,000 annually in salary, benefits, and travel before the first qualified opportunity. To cover the EU big-five, the US east and west coasts, Japan, and Korea, you need eight to ten reps with different language skills and therapeutic-area depth. Cost per qualified lead from field sales: $500 to $1,200+.

Cold calling across borders

To penetrate a buying committee at a single peptide customer, your team needs to reach CMC, analytical, regulatory, procurement, and supply-chain contacts. That means 20+ contact attempts per target account in the buyer’s native language, with deep technical credibility on SPPS, hybrid synthesis, and impurity profiling. Finding native German, French, Italian, Japanese, and Mandarin speakers who can also discuss racemization risk at scale is nearly impossible.

Across all of these channels, one structural flaw repeats: they reach one person at a time in an industry where peptide CDMO selection involves five to nine stakeholders across CMC, quality, regulatory, procurement, and supply chain.

How AI-Powered Outbound Reaches Peptide Buying Committees

AI-powered outbound is built for exactly this problem. Instead of waiting for the right CMC director to walk past your booth in Frankfurt, the system identifies who they are, where they are in their development timeline, and what message will earn their attention.

Multi-threaded outreach to entire CMC teams

A typical peptide CDMO selection decision involves the CMC director, analytical lead, regulatory affairs, head of procurement, supply-chain manager, and often the program lead in clinical operations. AI outbound identifies and engages all of them simultaneously. The CMC lead gets messaging about your SPPS capability, scale-up history, and analytical method development. Regulatory affairs sees your DMF filings and inspection track record. Procurement learns about supply continuity and dual-sourcing options. Each stakeholder gets role-appropriate technical content automatically.

Signal detection for peptide-specific buying intent

The system continuously monitors signals that indicate a real peptide need:

• Phase II clinical readouts for peptide assets (sponsors need GMP commercial supply within 18 to 24 months)
• Pre-IND meetings logged at FDA or EMA referencing peptide modalities
• Biosimilar GLP-1 program announcements in emerging-market sponsors
• CMC director or VP supply chain hires at biotech sponsors with peptide pipelines
• Patent filings referencing novel peptide sequences or peptide-drug conjugates
• Manufacturing capacity announcements by competitors that signal where they are saturated

When these signals appear, outreach arrives at the moment a buyer is most receptive, not eighteen months later when they show up at DCAT.

Technical content personalisation

Peptide buyers expect documentation depth before evaluating a new supplier: SPPS capability matrices, hybrid synthesis options, scale tables from 10 g to multi-tonne, analytical method development summaries, residual solvent and impurity profiling references, DMF and CEP filings, GMP audit history, and Swissmedic or FDA inspection outcomes. AI-powered outbound matches the right document to the right stakeholder automatically through the workflow described here.

What This Looks Like for a Mid-Sized Swiss Peptide CDMO

Consider a Swiss peptide CDMO in the greater Basel area with CHF 80 to CHF 200 million in annual revenue, GMP capacity from gram to multi-kilogram scale, and three or four anchor accounts.

With AI-powered outbound:

1. The system identifies 400 to 600 pharmaceutical and biotech companies globally with active peptide programs in clinical or pre-clinical stages
2. Buying committees are mapped: CMC directors, analytical leads, regulatory affairs, procurement, and supply-chain contacts at each target
3. Personalised outreach goes to each stakeholder with role-specific technical content in their working language
4. Signal detection flags a Phase II biotech that just dosed its first cohort with a novel GLP-1 analogue and will need commercial-scale supply within 24 months
5. A targeted sequence reaches the right contacts within days, before competitors notice the milestone

Cost per qualified lead with AI outbound: $150 to $300, dropping as the system learns which messaging, timing, and segmentation works best. Compare that to $300 to $900+ at trade fairs or $500 to $1,200+ through field reps. Traditional channels have a ceiling. AI outbound has a compounding floor.

Channel	Cost Per Qualified Lead	Scaling Behaviour
CPHI Frankfurt, DCAT, BIO-Europe	$300 to $900+	Linear. More fairs = proportionally more cost.
Field sales representatives	$500 to $1,200+	Worse than linear. Each rep adds salary with diminishing territory returns.
Distributor commissions	8 to 20% of deal value	Linear. More volume = more margin erosion. No direct buyer access.
AI-powered outbound	$150 to $300	Decreasing marginal cost. Better targeting and messaging over time.

The Structural Advantage Swiss Peptide CDMOs Have

Swiss peptide manufacturers carry a credibility premium that competitors in lower-cost geographies cannot match. Swissmedic and FDA inspection track records, GMP Annex 1 alignment, a workforce trained in the Merrifield-to-modern-SPPS lineage, and proximity to the Basel and Visp clusters all matter to a CMC director choosing between an Asian and a European supplier for a Phase III peptide program.

That credibility is wasted when it only reaches buyers who happen to attend the same trade fair. The companies that capture the next wave of peptide demand are those that bring their technical story directly to the CMC and procurement leads today. Context across Switzerland’s wider life-sciences base sits in our Swiss pharma and biotech export guide and the manufacturing export landscape.

Getting Started

Swiss peptide CDMOs do not need to abandon trade fairs or KOL networks. The path forward is additive:

1. Define the second-wave ICP. Beyond anchor pharma accounts, which mid-cap biotechs, biosimilar developers, oncology peptide sponsors, or ADC players represent the highest-value next 50 prospects?
2. Map buying committees. For each target, identify the CMC director, analytical lead, regulatory affairs head, procurement manager, and supply-chain lead
3. Prepare technical content per role. Organise SPPS capability summaries, analytical method development examples, DMF and CEP references, GMP certificates, and Swissmedic inspection outcomes for digital delivery
4. Launch multi-threaded campaigns. Begin coordinated outreach to complete buying committees, not just procurement
5. Measure and iterate. Track response rates by role, therapeutic area, signal type, and language

At papaverAI, we build AI-powered growth engines specifically for B2B manufacturers, including peptide and biologics CDMOs. We handle infrastructure, targeting, personalisation, and ongoing optimisation. Examples of how this has worked for other industrial and life-science clients are documented in our case studies.

Frequently Asked Questions

How large is the global peptide CDMO market?

The global peptide therapeutics CDMO market reached USD 2.9 billion in 2025 and is projected to grow to USD 9.0 billion by 2036 at a 10.8% CAGR. GLP-1 demand is the primary near-term driver, with biosimilars, oncology peptides, and ADC linkers expected to sustain growth through the next decade.

Why is GLP-1 demand reshaping the Swiss peptide CDMO landscape?

GLP-1 receptor agonists like semaglutide and tirzepatide require solid-phase peptide synthesis at commercial scale, which has historically been concentrated in a small number of Swiss, US, and Indian facilities. Tier-one CDMO lead times have extended 30 to 50% since 2023. Swiss anchors including Bachem, PolyPeptide, and Lonza are all expanding capacity, but second-wave demand from biosimilar developers and other metabolic peptide sponsors continues to outpace supply.

How does AI outbound help peptide CDMOs win new biotech accounts?

Peptide CDMO selection involves CMC, analytical, regulatory, procurement, and supply-chain stakeholders. AI outbound identifies all of them at target biotechs, personalises messaging by role, and times outreach to clinical and regulatory signals like Phase II readouts or pre-IND meetings. It generates qualified leads at $150 to $300 each, compared to $300 to $900+ from major pharma trade fairs and $500 to $1,200+ from field sales reps.

Is AI outbound suitable for highly regulated peptide sales?

Yes. AI outbound handles prospecting and initial engagement. All regulatory claims, DMF references, GMP certificates, and technical documentation are prepared by your team and delivered through the system. The AI personalises which content goes to which stakeholder. It does not generate regulatory claims or modify technical documents, which keeps Swissmedic, FDA, and EMA-relevant materials fully under your control.

How long until a Swiss peptide CDMO sees results?

Most B2B peptide outbound campaigns generate qualified responses within four to six weeks of launch. Given peptide CDMO sales cycles of nine to eighteen months for new programme qualification, first commercial contracts typically close within nine to fifteen months. The key advantage is building a consistent pipeline rather than relying on once-a-year CPHI or DCAT exhibitions.

---

Ready to build peptide CDMO pipeline that does not depend on the next trade fair? Get in touch with papaverAI to discuss how AI-powered outbound can complement your existing commercial team.